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ORIGINAL INVESTIGATION
Novel risk genes identified in a 
genome-wide association study for coronary 
artery disease in patients with type 1 diabetes
Romain Charmet1,2, Seamus Duffy3, Sareh Keshavarzi4, Beata Gyorgy1,2, Michel Marre5,6, Peter Rossing7,8, 
Amy Jayne McKnight3, Alexander P. Maxwell3, Tarun veer Singh Ahluwalia7, Andrew D. Paterson4,9, 
David‑Alexandre Trégouët1,2*†  and Samy Hadjadj10,11,12*†
Abstract 
Background: Patients with type 1 diabetes are more at risk of coronary artery disease than the general population. 
Although evidence points to a genetic risk there have been no study investigating genetic risk factors of coronary 
artery disease specific to individuals with type 1 diabetes. To identify low frequency and common genetic variations 
associated with coronary artery disease in populations of individuals with type 1 diabetes.
Methods: A two‑stage genome wide association study was conducted. The discovery phase involved the meta‑anal‑
ysis of three genome‑wide association cohorts totaling 434 patients with type 1 diabetes and coronary artery disease 
(cases) and 3123 T1D individuals with no evidence of coronary artery disease (controls). Replication of the top associa‑
tion signals (p < 10−5) was performed in five additional independent cohorts totaling 585 cases and 2612 controls.
Results: One locus (rs115829748, located upstream of the MAP1B gene) reached the statistical threshold of 5 × 10−8 
for genome‑wide significance but did not replicate. Nevertheless, three single nucleotide polymorphisms provided 
suggestive evidence for association with coronary artery disease in the combined studies: CDK18 rs138760780 
(OR = 2.60 95% confidence interval [1.75–3.85], p = 2.02 × 10−6), FAM189A2 rs12344245 (OR = 1.85 [1.41–2.43], 
p = 8.52 × 10−6) and PKD1 rs116092985 (OR = 1.53 [1.27–1.85], p = 1.01 × 10−5). In addition, our analyses suggested 
that genetic variations at the ANKS1A, COL4A2 and APOE loci previously found associated with coronary artery disease 
in the general population could have stronger effects in patients with type 1 diabetes.
Conclusions: This study suggests three novel candidate genes for coronary artery disease in the subgroup of 
patients affected with type 1 diabetes. The detected associations deserve to be definitively validated in additional 
epidemiological studies.
Keywords: Type 1 diabetes, Coronary artery disease, Diabetic nephropathy, Genome‑wide association study, Case 
control study, Epidemiology, Genetic association studies, Meta‑analysis
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Background
Type 1 diabetes (T1D) is a chronic disease characterized 
by an increase in blood glucose due to a lack of insulin 
production. Diabetes is a major health concern globally 
with a prevalence ranging between 4 and 7.8% in indus-
trialized countries [1, 2]; among persons with diabetes, it 
is estimated that 5–10% are affected with T1D [3]. Recent 
large-scale epidemiological studies suggest that T1D 
is associated with a reduced lifespan of approximately 
12  years [4] due to at least two-fold increased risk for 
death due to cardiovascular (CV) events.
Of note, in a nation-based registry of type 1 diabetes, 
coronary heart disease was 4 times more prevalent in 
patients with type 1 diabetes compared to sex- and age-
matched controls [5].
However, studies exploring cardiovascular disease 
(CVD) risk variants in T1D patients are lacking. Tradi-
tional risk factors for CVD including age, circulating 
lipid levels, and smoking are well established in the gen-
eral population [6] and in patients with type 1 diabetes 
[7]. Coronary artery disease (CAD) could be strongly 
influenced by genetic factors [8]. However, to the best of 
our knowledge, the relationship between genetic factors 
and CAD in type 1 diabetes was largely examined with 
a candidate gene approach [9–12]. Another important 
question is whether genetic markers of CAD established 
in the general population, known to roughly explain 10% 
of the heritability [13, 14], also play a role in individuals 
with T1D.
In an attempt to unravel the genetic determinants of 
CAD among T1D patients, we examined the association 
of genome-wide genotype array data with CAD in multi-
ple T1D cohorts of European descent (The British Isles, 
Denmark and France).
Materials and methods
General workflow
The present work reports the results of a two-stage 
research strategy for common genetic variations associ-
ated with CAD risk in T1D patients. The first (discovery) 
stage was based on the meta-analysis of three GWAS 
cohorts totaling 434 T1D patients with CAD (cases) and 
3123 T1D patients with no evidence of CAD (controls). 
The second stage consisted of a replication of the top dis-
covery signals with association p < 10−5 in five additional 
T1D studies totaling 585 cases and 2612 controls.
Participating cohorts for the discovery and replication 
stages
All participants were patients with T1D diagnosed using 
ADA criteria [15].
Controls were patients with T1D without history of 
CAD while cases were patients with T1D and a personal 
history of myocardial infarction or coronary artery revas-
cularization (coronary artery angioplasty or by-pass 
grafting).
The discovery phase was composed of European-ances-
try adults from (1) France (pooled cohorts of T1D from 
Corbeil Essonnes, Poitiers, Nantes, Paris, Toulouse [16] 
and two large scale multicenter cohorts i.e. GENESIS/
GENEDIAB [16]), (2) Denmark (After-EU cohort [17]) 
and (3) British Isles (UK-ROI study [18]). The replication 
phase included five independent T1D cohorts recruited 
in North America (Additional file 1: Table S1).
All participating studies were approved by their respec-
tive institutional review board/ethics committee and an 
informed consent was obtained from all participating 
individuals.
Genotype determinations and imputation
For each participating study, DNA samples were geno-
typed with high-density SNP arrays and further imputed 
for SNPs available in the 1000 Genomes reference data-
set. Summary descriptions of genotyping technologies, 
quality control procedures, and used imputation meth-
ods (MACH/Impute2) are shown in Additional file  1: 
Table S1.
Discovery phase: meta‑analysis of discovery GWAS
Association analyses of imputed SNPs with CAD risk 
were performed separately in each study. Analyses were 
performed using either of the MACH [19], Quicktest 
(http://toby.freeshell.org/software/quicktest.shtml), 
or Plink [20] analyses tools implementing a logistic 
regression model where the allele dosage represent-
ing the expected number of a given reference allele at 
the imputed SNP was used as covariate to estimate SNP 
effect. Analyses were adjusted for sex, age, DN status and 
potential population sub-structure as defined by SNPs 
derived principal components.
Only SNPs with acceptable imputation quality  (r2 > 0.3) 
in the three discovery cohorts and with estimated minor 
allele frequency (MAF) ≥ 1% were kept for meta-analy-
sis. This was performed by use of a fixed-effects model 
based on the inverse-variance weighting method as 
implemented in the METAL software [21]. The statistical 
threshold (p < 5 × 10−8) was used for declaring genome-
wide statistical significance while controlling for the 
number of independent tests across the genome. The 
Cochran’s Q statistic was used to assess heterogeneity 
of the SNP associations across studies whose magnitude 
was expressed by the I2 index [22]. Power calculations 
were performed using the CaTS power calculator (http://
csg.sph.umich.edu/abecasis/cats/) [23].
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Replication phase
Similar logistic regression models as those employed in 
the discovery were used for assessing the association of 
tested SNPs with CAD risk (Additional file 1: Table S1). 
Results obtained in the independent replication cohorts 
were then meta-analyzed using the same methodology 
as in the discovery step. The Bonferroni threshold corre-
sponding to 0.05 divided by the number of tested SNPs 
was used to declare statistical replication. Unilateral 
hypothesis testing was adopted at the replication stage. 
For SNPs that replicated, a meta-analysis of the com-
bined discovery and replications cohorts was performed 
to produce a more robust estimate of the effect size.
Results
A total of 6,728,637 imputed SNPs were tested for associa-
tion with CAD in 3557 T1D patients made of 434 with CAD 
cases and 3123 controls in the discovery dataset. The meta-
analysis results of the discovery GWAS have been summa-
rized in the Manhattan and QQ plots shown in Additional 
file 2: Figure S1, Additional file 3: Figure S2, respectively.
One locus at chromosome 5q13.2 reached genome-
wide significance (p < 5 × 10−8) with the lead SNP, 
rs115829748, located upstream of the MAP1B gene. The 
T allele of this low frequency SNP (MAF ~ 0.04), was 
associated with an Odds Ratio (OR) of 3.16 [95% confi-
dence interval (CI) 2.18–4.59] (p = 1.36 × 10−9). No other 
SNP demonstrated suggestive association with CAD at 
this locus (Additional file 4: Figure S3).
At the p < ~ 1.0 × 10−5 threshold, 20 additional loci 
demonstrated evidence for suggestive association with 
CAD with little heterogeneity across cohorts (Table  1). 
Imputation metrics of the top SNPs are provided in the 
Additional file 5: Table S2. Therefore, we sought to rep-
licate the top 21 signals in five independent T1D cohorts 
totaling 585 CAD cases and 2612 controls. Replication 
was feasible for 17 SNPs while four SNPs (rs34319244, 
rs373009901, rs143723948, rs571622299) were not prop-
erly imputed in the replication stage (Table  1). While 
none of the 17 SNPs reached the pre-specified Bonfer-
roni threshold of 3.0 × 10−3 for positive statistical replica-
tion, three were however nominally (p < 0.05) associated 
with CAD in the replication stage, with genetic effects 
consistent between the discovery and replication studies 
(Table 1). Of note, no trend for association was observed 
(p = 0.279) with the MAP1B rs115829748 that came out 
first in the discovery GWAS and that showed similar 
allele frequencies in the discovery and replication studies.
The strongest association was observed at the CDK18 
locus where, in the replication stage, the rs138760780-
T allele, with frequency 0.02, was associated with an 
increased odds ratio (OR) for disease of 1.88 [1.07–
3.31] (p = 0.014). This value has to compare with 3.48 
[2.00–6.04] observed in the discovery cohorts. In the 
combined discovery and replication cohorts, the meta-
analyzed OR associated with the rs138760780 T allele was 
2.60 [1.75–3.85] (p = 2.02 × 10−6) with no heterogeneity 
across the discovery and replication stage (p = 0.545).
The second suggestive association holds at the 
FAM189A2 locus. The rs12344245-G allele found associ-
ated with an increased OR of 2.52 [1.68–3.81] in the dis-
covery cohorts also demonstrated a trend for association 
with the disease in the replication stage, OR = 1.45 [1.01–
2.08] (p = 0.022). Combining the discovery and replica-
tion study led to a meta-analyzed OR for disease of 1.85 
[1.41–2.43] (p = 8.52 × 10−6) with no significant evidence 
for heterogeneity across stage (p = 0.426).
The third suggestive association was observed for the 
PKD1 locus. The rs116092985 minor G associated with 
a 1.85 [1.408–2.44] and a 1.29 [1.00–1.67] increased 
risk of CAD in the discovery and replication cohorts, 
respectively. Altogether, the combined statistical evi-
dence for association of the rs116092985-G allele reached 
p = 1.01 × 10−5 (OR = 1.53 [1.27–1.85]) (p = 0.220 for 
heterogeneity across studies).
Candidate CAD SNPs
About 90 loci have been found, through GWAS studies, 
to harbor common susceptibility alleles associated with 
CAD in the general population. We sought to investi-
gate how these loci associate with CAD in T1D patients. 
Results of this investigation are summarized in Table  2. 
From CAD SNPs identified in previous GWAS [13, 14, 
24–26], 95 were well imputed in our discovery phase 
and showed genetic effects with directionality in our 
T1D populations that were consistent with those previ-
ously reported (Table  2). Imputation quality for these 
95 SNPs is given in Additional file 6: Table S3. For three 
SNPs ANKS1A_rs17609940, COL4A2_rs11838776 and 
TOMM40_rs2075650 (near the APOE locus), the statisti-
cal evidence for association with the disease was rather 
strong with p < 5 × 10−3 even though it did not achieve 
multiple testing correction for the number of tested SNPs 
(~ 5 × 10−4 = 0.05/95). For these three SNPs, the ampli-
tude of the genetic association even tended to be stronger 
in our T1D patients than that previously reported 
(Table 2). As an illustration, in our discovery T1D popu-
lation, the COL4A1 rs11838776-A allele was associated 
with an OR of 1.33 [1.11–1.61] while the OR reported in 
the literature was slightly lower (OR = 1.07). Conversely, 
the association of the polymorphism at the non-coding 
ANRIL loci on 9p21, that is known to associate the most 
with CAD among common polymorphisms, showed a 
very similar association in our T1D patients (OR = 1.16 
[0.993–1.362], p = 0.03) compared to that previously 
reported (OR ~ 1.21).
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Table 2 Replication of CAD SNPs previously identified in the general population
SNP CHR BP Locus Published GWAS results Discovery GWAS in T1D patients
EAa EAFb ORc EAFd ORe [95% CI] Pf Directiong Powerh
rs11206510 1 55496039 PCSK9 T/C 0.848 1.08 0.815 1.08 [0.883–1.324] 0.223 −++ 0.150
rs9970807 1 56965664 PPAP2B C/T 0.915 1.13 0.906 1.21 [0.904–1.625] 0.098 +++ 0.380
rs7528419 1 109817192 SORT1 A/G 0.786 1.12 0.784 1.11 [0.918–1.348] 0.138 +++ 0.260
rs11810571 1 151762308 TDRKH G/C 0.849 1.06 0.854 1.05 [0.836–1.316] 0.339 −+− 0.080
rs1892094 1 169094459 ATP1B1 T/C 0.500 0.96 0.529 1.08 [0.919–1.266] 0.822 −++ 0.200
rs6700559 1 200646073 DDX59 T/C 0.470 0.96 0.460 1.15 [0.982–1.338] 0.958 +−+ 0.520
rs2820315 1 201872264 LMOD1 T/C 0.300 1.05 0.298 0.97 [0.820–0.156] 0.618 −++ 0.060
rs17464857 1 222762709 MIA3 T/G 0.861 1.06 0.842 1.12 [0.901–1.405] 0.148 +++ 0.250
rs16986953 2 19942473 AK097927 A/G 0.105 1.09 0.075 1.07 [0.799–1.450] 0.314 +++ 0.080
rs7567217 2 21303470 APOB T/C 0.860 1.07 0.858 1.02 [0.811–1.297] 0.415 −+ 0.060
rs7568458 2 85788175 GGCX A/T 0.449 1.06 0.460 1.06 [0.904–1.247] 0.232 +−+ 0.140
rs17678683 2 145286559 ZEB2 G/T 0.088 1.10 0.079 1.23 [0.900–1.692] 0.095 +− 0.390
rs2252641 2 145801461 ZEB2 C/T 0.475 1.03 0.450 1.01 [0.867–1.186] 0.430 ++− 0.050
rs1250229 2 216304384 FN1 T/C 0.256 1.07 0.260 0.88 [0.730–1.060] 0.911 − 0.390
rs2571445 2 218683154 TNS1 A/G 0.390 1.04 0.388 1.05 [0.894–1.234] 0.275 +−+ 0.110
rs1801251 2 233633460 KCNJ13 A/G 0.350 1.05 0.344 1.15 [0.975–1.352] 0.049 ++− 0.490
rs7623687 3 49448566 RHOA A/C 0.855 1.08 0.864 0.96 [0.756–1.212] 0.626 +++ 0.060
rs142695226 3 124475201 ITGB5 G/T 0.138 1.07 0.152 0.95 [0.754–1.195] 0.672 −+− 0.090
rs201477372 3 138099161 MRAS TTTC/T 0.163 1.08 0.155 1.02 [0.829–1.264] 0.411 −+− 0.060
rs12493885 3 153839866 ARHGEF26 C/G 0.886 1.07 0.866 0.87 [0.691–1.089] 0.890 +− 0.260
rs17087335 4 57838583 NOA1 T/G 0.210 1.06 0.177 0.99 [0.812–1.215] 0.523 −++ 0.050
rs10857147 4 81181072 FGF5 T/A 0.275 1.05 0.282 1.02 [0.855–1.215] 0.417 ++− 0.060
rs7678555 4 120909501 MAD2L1 C/A 0.301 1.05 0.287 0.92 [0.770–1.100] 0.818 −+ 0.200
rs4593108 4 148281001 MIR548G C/G 0.795 1.07 0.831 0.93 [0.761–1.145] 0.743 +− 0.110
rs1878406 4 148393664 EDNRA C/T 0.844 0.94 0.894 0.94 [0.740–1.208] 0.328 −+ 0.070
rs72689147 4 156639888 GUCY1A3 G/T 0.817 1.07 0.812 1.13 [0.919–1.390] 0.122 +++ 0.300
rs273909 5 131667353 SLC22A4 G/A 0.117 1.06 0.104 0.94 [0.726–1.217] 0.680 − 0.090
rs246600 5 142516897 ARHGAP26 T/C 0.480 1.05 0.486 0.98 [0.839–1.155] 0.575 −+− 0.060
rs9349379 6 12903957 PHACTR1 G/A 0.432 1.14 0.392 1.07 [0.919–1.267] 0.174 +++ 0.200
rs7454157 6 12909874 PHACTR1 G/A 0.651 1.10 0.622 1.15 [0.978–1.371] 0.044 +++ 0.550
rs6909752 6 22612629 HDGFL1 A/G 0.351 1.05 0.374 1.01 [0.851–1.186] 0.476 −+− 0.050
rs3130683 6 31888367 C2 T/C 0.860 1.09 0.960 0.69 [0.455–1.034] 0.964 +− 0.580
rs17609940 6 35034800 ANKS1A G/C 0.824 1.03 0.796 1.32 [1.077–1.635] 0.004 +++ 0.890
rs56336142 6 39134099 KCNK5 T/C 0.807 1.07 0.786 1.04 [0.860–1.265] 0.333 +− 0.080
rs10947789 6 39174922 KCNK5 T/C 0.775 1.05 0.753 1.07 [0.890–1.293] 0.229 +−+ 0.150
rs12202017 6 134173151 TCF21 A/G 0.700 1.07 0.713 1.02 [0.856–1.215] 0.411 +− 0.060
rs12190287 6 134214525 TCF21 C/G 0.617 1.06 0.633 1.06 [0.896–1.270] 0.232 +− 0.150
rs2048327 6 160863532 SLC22A3 T/C 0.646 0.94 0.633 1.00 [0.854–1.188] 0.538 −+− 0.050
rs3798220 6 160961137 LPA T/C 0.975 0.70 0.986 0.74 [0.397–1.393] 0.178 +− 0.140
rs55730499 6 161005610 LPA T/C 0.056 1.37 0.079 1.22 [0.925–1.609] 0.078 +0+ 0.350
rs4252185 6 161123451 PLG C/T 0.060 1.34 0.087 1.15 [0.862–1.541] 0.168 +++ 0.210
rs4252120 6 161143608 PLG T/C 0.740 1.03 0.709 0.91 [0.766–1.084] 0.852 −+ 0.240
rs2023938 7 19036775 HDAC9 T/C 0.897 0.94 0.899 0.87 [0.679–1.135] 0.161 +− 0.200
rs2107595 7 19049388 HDAC9 A/G 0.200 1.08 0.174 1.14 [0.926–1.406] 0.106 +++ 0.310
rs12539895 7 107091849 COG5 C/A 0.807 1.04 0.788 1.14 [0.931–1.394] 0.101 +−+ 0.350
rs10953541 7 107244545 BCAP29 C/T 0.783 1.05 0.750 1.16 [0.967–1.401] 0.054 ++− 0.490
rs11556924 7 129663496 ZC3HC1 C/T 0.687 1.08 0.593 0.97 [0.832–1.147] 0.610 −+ 0.060
rs10237377 7 139757136 PARP12 T/G 0.350 0.95 0.362 0.91 [0.766–1.084] 0.148 −+− 0.260
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Table 2 continued
SNP CHR BP Locus Published GWAS results Discovery GWAS in T1D patients
EAa EAFb ORc EAFd ORe [95% CI] Pf Directiong Powerh
rs3918226 7 150690176 NOS3 T/C 0.060 1.14 0.088 0.90 [0.672–1.212] 0.751 −++ 0.140
rs264 8 19813180 LPL G/A 0.853 1.06 0.846 0.94 [0.756–1.168] 0.711 −+ 0.100
rs2954029 8 126490972 TRIB1 A/T 0.551 1.04 0.529 1.05 [0.896–1.232] 0.269 ++− 0.110
rs3217992 9 22003223 CDKN2BAS1 C/T 0.607 0.88 0.614 0.92 [0.789–1.084] 0.169 − 0.200
rs2891168 9 22098619 CDKN2BAS1 G/A 0.489 1.21 0.505 1.16 [0.993–1.362] 0.030 +++ 0.6
rs2519093 9 136141870 ABO T/C 0.191 1.08 0.186 0.98 [0.800–1.203] 0.571 −++ 0.060
rs2487928 10 30323892 KIAA1462 A/G 0.418 1.06 0.458 1.08 [0.924–1.271] 0.161 −++ 0.220
rs2624695 10 44549767 CXCL12 C/T 0.534 0.94 0.503 1.08 [0.926–1.270] 0.843 +++ 0.220
rs501120 10 44753867 CXCL12 T/C 0.813 1.08 0.863 1.18 [0.927–1.508] 0.088 +++ 0.400
rs11203043 10 90989279 LIPA G/A 0.576 1.04 0.551 0.89 [0.764–1.052] 0.909 − 0.360
rs1412444 10 91002927 LIPA T/C 0.369 1.07 0.326 0.94 [0.798–1.116] 0.749 −+− 0.130
rs11191416 10 104604916 CYP17A1 T/G 0.873 1.08 0.915 0.90 [0.686–1.186] 0.768 +− 0.120
rs11042937 11 10745394 MRVI1‑CTR9 T/G 0.490 1.04 0.499 1.06 [0.908–1.248] 0.220 ++− 0.150
rs3993105 11 13303071 ARNTL T/C 0.704 1.05 0.693 1.03 [0.866–1.228] 0.364 −+− 0.070
rs12801636 11 65391317 PCNX3 A/G 0.230 0.95 0.225 0.98 [0.810–1.189] 0.425 +− 0.060
rs590121 11 75274150 SERPINH1 T/G 0.300 1.05 0.295 0.80 [0.669–0.961] 0.992 − 0.830
rs9319428 13 28973621 FLT1 A/G 0.314 1.04 0.289 1.03 [0.874–1.227] 0.339 −++ 0.070
rs4773144 13 110960712 COL4A2 A/G 0.572 0.95 0.555 0.99 [0.850–1.172] 0.493 −++ 0.050
rs11838776 13 111040681 COL4A2 A/G 0.263 1.07 0.284 1.33 [1.113–1.606] 0.001 ++− 0.980
rs9515203 13 111049623 COL4A2 T/C 0.761 1.07 0.736 1.20 [0.983–1.468] 0.036 +++ 0.650
rs10139550 14 100145710 HHIPL1 G/C 0.423 1.06 0.413 0.96 [0.819–1.145] 0.645 −+ 0.070
rs6494488 15 65024204 RBPMS2 G/A 0.180 0.95 0.151 1.01 [0.803–1.280] 0.545 +− 0.050
rs56062135 15 67455630 SMAD3 C/T 0.790 1.07 0.758 1.07 [0.893–1.302] 0.214 ++− 0.160
rs7173743 15 79141784 ADAMTS7 T/C 0.564 1.08 0.515 1.00 [0.855–1.171] 0.495 −++ 0.050
rs8042271 15 89574218 ABHD2 G/A 0.900 1.10 0.947 0.93 [0.602–1.457] 0.613 −+ 0.070
rs17514846 15 91416550 FURIN‑FES A/C 0.440 1.05 0.461 1.08 [0.924–1.267] 0.163 ++− 0.210
rs1800775 16 56995236 CETP C/A 0.510 1.04 0.524 0.99 [0.844–1.153] 0.568 −+− 0.050
rs1050362 16 72130815 DHX38 A/C 0.380 1.04 0.351 1.11 [0.939–1.313] 0.110 +−+ 0.310
rs7500448 16 83045790 CDH13 A/G 0.752 1.06 0.755 1.09 [0.894–1.321] 0.202 +−+ 0.190
rs216172 17 2126504 SMG6 C/G 0.350 1.05 0.368 1.13 [0.963–1.329] 0.067 +++ 0.420
rs12936587 17 17543722 RAI1 G/A 0.611 1.03 0.542 1.00 [0.857–1.174] 0.480 −++ 0.050
rs17608766 17 45013271 GOSR2 C/T 0.140 1.07 0.133 0.89 [0.705–1.121] 0.840 − 0.220
rs999474 17 46987665 UBE2Z G/A 0.600 1.04 0.572 0.92 [0.789–1.084] 0.832 − 0.130
rs7212798 17 59013488 BCAS3 C/T 0.150 1.08 0.155 0.98 [0.786–1.221] 0.570 −++ 0.060
rs1867624 17 62387091 PECAM1 C/T 0.390 0.96 0.377 1.06 [0.898–1.241] 0.744 +++ 0.130
rs663129 18 57838401 U4/MC4R A/G 0.260 1.06 0.237 1.01 [0.847–1.227] 0.418 ++− 0.060
rs1122608 19 11163601 LDLR G/T 0.770 1.07 0.756 0.87 [0.731–1.048] 0.926 +− 0.380
rs56289821 19 11188247 LDLR G/A 0.900 1.14 0.880 1.10 [0.855–1.427] 0.223 +−+ 0.170
rs12976411 19 32882020 ZNF507 A/T 0.910 1.61 0.958 0.96 [0.639–1.460] 0.564 −+ 0.050
rs8108632 19 41854534 TGFB1 T/A 0.488 1.05 0.445 1.11 [0.938–1.307] 0.113 ++− 0.330
rs2075650 19 45395619 TOMM40 A/G 0.865 0.93 0.869 0.74 [0.596–0.919] 0.003 − 0.870
rs445925 19 45415640 APOE/APOC1 G/A 0.902 1.09 0.893 0.87 [0.681–1.129] 0.844 ++− 0.210
rs4420638 19 45422946 APOE/APOC1 G/A 0.166 1.10 0.171 1.20 [0.985–1.461] 0.034 +−+ 0.530
rs1964272 19 46190268 SNRPD2 G/A 0.510 1.05 0.509 0.95 [0.805–1.113] 0.747 −+ 0.110
rs867186 20 33764554 PROCR G/A 0.110 0.93 0.094 1.26 [0.974–1.623] 0.961 +++ 0.490
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Discussion
The present work was aimed at identifying suscepti-
bility alleles for CAD risk in patient population of T1D 
using a GWAS approach with a two-step framework 
(discovery + replication). Albeit we identified one locus 
(MAP1B) reaching genome-wide significance in the dis-
covery stage, it did not replicate with similar effects. Nev-
ertheless, in the combined T1D dataset of 1019 cases and 
5735 controls, we observed strong statistical evidence for 
association with CAD at three biological candidate genes, 
CDK18, PKD1 and FAM189A2.
We consider our study as very original as it is the 
first one, to the best of our knowledge, to use a GWAS 
approach for CAD, in patients with type 1 diabetes. We 
have thus pooled the largest collection of type 1 diabetes 
patients with available genetic data.
The low frequency CDK18 rs138760780-T allele (fre-
quency ~ 0.02) was found associated with ~ 2.5 fold 
increased risk of CAD. According to public database (e.g. 
Haploreg [27]), this SNP does not show strong linkage 
disequilibrium (LD) (pairwise  r2 > 0.80) with other SNPs 
at this locus, consistent with the regional association 
plot that does not suggest any evidence of disease asso-
ciated SNPs (Additional file  7: Figure S4). Interrogating 
the functional status of this SNP through HaploReg tool 
[27] suggested that this SNP may be involved in some 
epigenetic regulatory mechanisms. CDK18 encodes for 
a cyclin-dependent kinase, suggesting a role in cell cycle. 
This predicted protein is also related to CDK1, which is 
involved in the G2/M transition in eukaryotic cells [28]. 
Although cell cycle is a very broad pathway, CDK1 has 
also been associated with T1D [29], but at this point little 
is known about a potential involvement of CDK18 in the 
pathophysiology of T1D or its complications.
We also observed some evidence that the low frequency 
FAM189A2 rs12344245 G allele, (frequency ~ 0.04), asso-
ciated with a ~ 1.8 fold-increased risk of CAD. We did 
not find any evidence suggesting that this intronic SNP, 
or any other SNPs in LD (Additional file  8: Figure S5: 
regional association plot) with it, could be functional. 
Nevertheless, even though not much is known about the 
role of the encoded protein, this locus is a good candi-
date. Indeed, genetic variations at this locus have been 
found associated with albumin to creatinine ratio [30]. 
More interestingly, two FAM189A2 SNPs (rs10780297 
and rs10120442) have been reported to moderately 
associate (p = 9.3 × 10−4) in a large GWAS for CAD 
in ~ 63,000 non-diabetic populations [14], suggesting 
that this locus could be a CAD locus in some specific 
at-risk groups of diabetic patients. The latter two SNPs 
are in moderate LD (D’ = 1 but  r2 = 0.05) with our lead 
rs12344245 SNP, indicating that a fine mapping analysis 
of this locus would warrant further investigations. Of 
interest, it was not identified as a common gene in both 
type 2 diabetes and CAD. It can thus be speculated this 
gene is an important gene in high-glucose environment 
rather than a gene leading to high-glucose.
Finally, we observed an association of the non-syn-
onymous PKD1 rs116092985 (Trp1399Arg) with CAD 
among T1D patients where the Arg1399 minor allele (fre-
quency ~ 0.10), was associated with an increased CAD 
risk (OR ~ 1.5). The regional plot (Additional file  9: Fig-
ure S6) shows that there are several SNPs in LD with this 
PKD1 top SNP that associate with CAD. PKD1 encodes 
for the Polycystin 1, Transient Receptor Potential Chan-
nel Interacting protein, a member of the polycystin pro-
tein family. Recent reports have suggested a role of PKD1 
not only in renal tubular function and structure [31] 
a Estimated allele/non estimated allele
b Allele frequency of the estimate allele reported in [14, 24–26]
c Odds ratio for CAD reported in [14, 24–26]
d Allele frequency of the estimated allele in the discovery GWAS of T1D patients
e Odds ratio for CAD [95% confidence interval] observed in the discovery GWAS of T1D patients
f One sided test p value of association
g Directionality of the effects across the contributing cohorts
h Power estimates were provided by the CaTS program [23] and correspond to the power of our discovery GWAS to achieve 0.05 statistical significance at the 
observed associations based on  EAFd and  ORe under the assumption of a multiplicative model (on log-scale)
SNP CHR BP Locus Published GWAS results Discovery GWAS in T1D patients
EAa EAFb ORc EAFd ORe [95% CI] Pf Directiong Powerh
rs28451064 21 35593827 KCNE2 A/G 0.121 1.14 0.126 1.36 [1.066–1.751] 0.006 +−+ 0.890
rs180803 22 24658858 POM121L9P G/T 0.970 1.20 0.979 1.18 [0.510–2.743] 0.348 −++ 0.120
Table 2 continued
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but rare mutations in this gene as the main also cause 
underlying polycystic kidney disease [32], highlighting 
its importance in kidney complications. One impor-
tant question is whether PKD1 risk allele is involved in a 
common genetic background linking DN and CAD. This 
question was not duly analyzed due to power issue. How-
ever, no clear association was established with DN in pre-
vious GWAS focusing on this question [18].
Our study also enabled us to assess in patients with 
T1D the impact of common SNPs that have been found 
associated with CAD in large GWAS performed in unse-
lected individuals. Beyond the observation that most of 
the previously reported SNPs showed consistent associa-
tion with CAD in our T1D population, this look-up iden-
tified a few CAD loci (ANKS1A, COL4A2, TOMM40/
APOE) where the reported CAD associated SNP could 
have a stronger effect in T1D patients. However, this 
hypothesis would require further investigation.
Some limitations must be acknowledged. We did not 
consider differently T1D patients with and without DN, 
and all of the analyses were not stratified on DN status 
in order to keep all CAD patients in the analysis. How-
ever, this should have limited impact on our main results 
as none of the SNPs identified here were positive con-
sidering previously reported GWAS with regard to DN 
as primary endpoint [18]. Another limitation pertains to 
limited power of our sample size required, particular to 
overcome the harsh genome-wide statistical significance 
threshold. Indeed, our discovery GWAS was not well 
powered to identify common SNPs associated with mod-
erate genetic effects as those frequently encountered in a 
GWAS context. For instance, our discovery study had no 
power to detect at the genome-wide statistical threshold 
the genetic effect of a variant with an associated allelic 
OR less than 1.40. It was only well powered (> 80%) to 
detect OR greater than 1.6 as soon as the allele frequency 
of the disease allele is greater than 0.28 and well pow-
ered to detect OR greater than ~ 2 for allele frequency 
greater than 0.05. In particular, we had no power to 
detect the well-established association of the 9p21 locus 
at the 5 × 10−8 threshold while we had a chance of 60% 
to detect it would the liberal threshold of 0.05 had been 
used. Similarly, we acknowledge the low power of our 
replication studies where none of the tested associations 
achieved the Bonferroni threshold of 3 × 10−3. We only 
had a power of 53, 38 and 26% to detect at this threshold 
a significant association at the CDK18 rs13876070, PKD1 
rs116092985 and the FAM189A2 loci, respectively.
Despite these limitations, we have assembled the larg-
est cohort available and conducted novel analyses to dis-
cover novel candidate loci for CAD in T1D patients that 
need to be further studied with additional epidemiologi-
cal data and functional work to confirm our findings. Of 
interest, our negative study could suggest a role of epige-
netics beyond genomics. In this regard, insulin promotes 
the expression of DNA methyltransferases leading to 
methylation resulting in atherosclerosis [33], broadening 
the research field of CAD in type 1 diabetes.
Conclusions
We identified three new candidate loci for CAD in indi-
viduals with T1D, these loci weren’t previously found 
associated with CAD in the general population. Three 
other loci previously reported in the general population 
were found associated with CAD in our setting, namely 
ANKS1A, COL4A2 and TOMM40/APOE. Although this 
work needs further investigation, studying the function 
of these loci could lead to a better understanding of the 
physiological pathways involved in the development of 
CAD as a complication of T1D.
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